Maestros Electronics & Telecommun. Systems Ltd
Incorporated in 2010, Maestros Electronics & Telecommunications Systems Ltd is in the business of manufacturing medical equipment and telemedicine.[1]
- Market Cap ₹ 107 Cr.
- Current Price ₹ 97.4
- High / Low ₹ 130 / 53.2
- Stock P/E 11.2
- Book Value ₹ 42.0
- Dividend Yield 0.00 %
- ROCE 23.5 %
- ROE 19.3 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Debtor days have improved from 97.3 to 75.2 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Industrials Capital Goods Industrial Manufacturing Industrial Products
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.54 | 11.04 | 12.86 | 9.22 | 9.53 | 13.54 | 47.55 | 11.15 | 24.60 | 33.29 | 28.89 | 39.17 | 47.94 | |
| Sales growth | +15.66% | -33.25% | +16.49% | -28.30% | +3.36% | +42.08% | +251.18% | -76.55% | +120.63% | +35.33% | -13.22% | +35.58% | +64.29% |
| 15.09 | 10.27 | 11.38 | 9.47 | 8.87 | 11.94 | 39.06 | 10.11 | 20.93 | 27.37 | 24.75 | 31.66 | 37.84 | |
| Operating Profit | 1.45 | 0.77 | 1.48 | -0.25 | 0.66 | 1.60 | 8.49 | 1.04 | 3.67 | 5.92 | 4.14 | 7.51 | 10.10 |
| OPM % | 8.77% | 6.97% | 11.51% | -2.71% | 6.93% | 11.82% | 17.85% | 9.33% | 14.92% | 17.78% | 14.33% | 19.17% | 21.07% |
| 0.55 | 0.84 | 0.52 | 0.82 | 0.58 | 0.47 | 0.96 | 1.48 | 1.26 | 2.24 | 2.43 | 2.20 | 2.74 | |
| Interest | 0.42 | 0.32 | 0.37 | 0.33 | 0.31 | 1.10 | 1.37 | 0.46 | 0.52 | 0.80 | 0.48 | 0.39 | 0.37 |
| Depreciation | 0.56 | 0.65 | 0.60 | 0.44 | 0.46 | 0.45 | 0.36 | 0.37 | 0.39 | 0.45 | 0.39 | 0.48 | 0.48 |
| Profit before tax | 1.02 | 0.64 | 1.03 | -0.20 | 0.47 | 0.52 | 7.72 | 1.69 | 4.02 | 6.91 | 5.70 | 8.84 | 11.99 |
| Tax % | 32.35% | 31.25% | 32.04% | 25.00% | 25.53% | 32.69% | 26.94% | 25.44% | 25.87% | 28.51% | 23.16% | 19.46% | |
| 0.69 | 0.45 | 0.70 | -0.25 | 0.34 | 0.35 | 5.64 | 1.25 | 2.98 | 4.94 | 4.38 | 7.13 | 9.18 | |
| EPS in Rs | 0.93 | 0.57 | 0.81 | -0.27 | 0.34 | 0.33 | 5.13 | 1.14 | 2.71 | 4.49 | 3.98 | 6.48 | 8.34 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 22.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -4% |
| 3 Years: | 17% |
| TTM: | 64% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 6% |
| 3 Years: | 36% |
| TTM: | 154% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 31% |
| 3 Years: | 32% |
| 1 Year: | 76% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 14% |
| 3 Years: | 17% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.68 | 3.97 | 4.31 | 4.71 | 4.94 | 5.24 | 5.51 | 5.51 | 5.51 | 5.51 | 5.51 | 5.51 | 5.51 |
| Reserves | 5.97 | 7.41 | 8.06 | 8.24 | 9.41 | 10.12 | 16.08 | 17.05 | 20.06 | 25.02 | 29.37 | 36.53 | 40.75 |
| 3.99 | 2.59 | 3.88 | 2.61 | 2.56 | 8.23 | 2.10 | 2.10 | 4.79 | 5.35 | 3.60 | 1.62 | 3.26 | |
| 6.00 | 6.87 | 5.87 | 5.98 | 5.17 | 16.90 | 34.39 | 29.43 | 11.99 | 21.39 | 20.49 | 20.55 | 13.69 | |
| Total Liabilities | 19.64 | 20.84 | 22.12 | 21.54 | 22.08 | 40.49 | 58.08 | 54.09 | 42.35 | 57.27 | 58.97 | 64.21 | 63.21 |
| 6.38 | 5.89 | 8.44 | 8.09 | 8.22 | 8.01 | 7.89 | 7.85 | 8.46 | 8.21 | 9.00 | 9.22 | 9.76 | |
| CWIP | 1.36 | 2.82 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.71 | 5.59 | 7.06 | 6.61 |
| Investments | 0.14 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 |
| 11.76 | 11.99 | 13.68 | 13.45 | 13.86 | 32.48 | 50.19 | 46.24 | 33.89 | 45.35 | 43.38 | 46.93 | 45.84 | |
| Total Assets | 19.64 | 20.84 | 22.12 | 21.54 | 22.08 | 40.49 | 58.08 | 54.09 | 42.35 | 57.27 | 58.97 | 64.21 | 63.21 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.83 | 1.00 | -1.39 | -1.91 | -0.85 | -3.55 | 27.69 | -8.47 | -5.76 | 7.25 | 5.63 | 1.66 | |
| -1.33 | -1.48 | 0.26 | 0.56 | 0.27 | 1.99 | 1.95 | 0.91 | 3.55 | -7.02 | -5.24 | -0.89 | |
| 0.63 | 0.47 | 0.68 | 0.47 | 0.23 | 2.09 | -4.50 | -0.74 | 1.65 | -0.24 | -0.39 | -0.77 | |
| Net Cash Flow | 1.12 | -0.02 | -0.45 | -0.88 | -0.36 | 0.53 | 25.15 | -8.30 | -0.56 | -0.01 | 0.00 | 0.00 |
| Free Cash Flow | 0.09 | -0.62 | -1.71 | -1.82 | -1.45 | -3.79 | 27.45 | -8.96 | -6.84 | 3.34 | 2.55 | -0.47 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 126% | 156% | -70% | 708% | -129% | -176% | 328% | -814% | -150% | 145% | 180% | 38% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 73.71 | 105.80 | 96.78 | 91.45 | 107.24 | 83.30 | 94.49 | 384.64 | 149.12 | 172.36 | 44.35 | 75.20 |
| Inventory Days | 20.24 | 34.11 | 83.72 | 172.85 | 221.61 | 524.81 | 179.81 | 359.80 | 142.55 | 67.52 | ||
| Days Payable | 137.12 | 309.85 | 199.24 | 318.37 | 221.61 | 153.48 | 137.38 | 236.18 | 85.58 | 41.91 | ||
| Cash Conversion Cycle | -43.17 | -169.94 | -18.74 | -54.07 | 107.24 | 454.62 | 94.49 | 384.64 | 191.54 | 295.98 | 101.32 | 100.80 |
| Working Capital Days | -106.15 | -165.64 | -94.51 | -91.84 | -28.73 | 120.23 | -138.17 | -284.47 | 2.52 | -35.96 | -64.56 | -8.48 |
| ROCE % | 11.29% | 6.95% | 9.27% | 0.82% | 4.80% | 8.00% | 38.45% | 8.98% | 16.32% | 23.28% | 16.68% | 23.47% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electronics & Instrumentation Segment Revenue INR Lakhs |
|
|||||||||||
| Export Revenue INR Lakhs |
||||||||||||
| Telemedicine / Medical Segment Revenue INR Lakhs |
||||||||||||
| Number of Permanent Employees count |
||||||||||||
| Capital Expenditure on Property, Plant & Equipment INR Lakhs |
||||||||||||
| R&D Expenses (P&L line item) INR Lakhs |
||||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication
-
Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026, Approved And Considered By The Board At The Board Meeting Of The Company Held Today I.E., Thursday, November 05, 2026.
- Board approved unaudited standalone and consolidated Q2/H1 FY2026-27 results on November 5, 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today I.E. Thursday, November 05, 2026
- Board approved unaudited standalone and consolidated results for quarter and half year ended September 30, 2026.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
- Received domestic PO from Tamilnadu Medical Services Corporation for 100 Multipara Monitors worth Rs. 74.86 lakh.
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
- Received Rs 1.67 crore order from Mazagon Dock for 81 telemedicine products for Indian Navy, executing by March 3, 2027.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
Business Overview:[1]
METSL is engaged in activities related to the design, development, and manufacturing of products and services for financial inclusion, cardiology, gynecology, critical care patient and disease management in medicine. It offers an advanced portfolio of products and services, including patient monitors, pulse oximeters, electrocardiographs, defibrillators, fetal monitors, stress test systems, etc.